Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Path For Cocaine Addiction Research
Cocaine is one of the oldest drugs known to humans, and its abuse has become widespread since the end of the 19th century. At the same time, we know rather little about its effects on the human brain or the mechanisms that lead to cocaine addiction. The latest article by Dr. Marco Leyton, of the Montreal Neurological Institute (MNI), McGill University and the McGill University Health Centre, which was published in the journal Biological Psychiatry on May 15, 2009, not only demonstrates a link between cocaine and the reward circuits in the brain but also associates the susceptibility to addiction with these mechanisms.

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect").
News of the day
Shocking New Figures Of Diabetes Complications Released, UK
New figures from the NHS Information Centre reveal a sobering tally of over 300 heart attacks, 300 strokes, 65 foot or toe amputations and 38 leg amputations among people with diabetes each week.
Nutrition

New MedPredict Report Reveals Top Alzheimer's Experts' Insights On Diagnostics And Treatments In Development Pipeline

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer"s Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned Alzheimer"s disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to Jeff Berk, MedPredict"s president and lead author of this report. "The panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer"s disease and treatment at the earliest stages of dementia." "The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and drugs like Dimebon, specifically designed to enhance mental function," says Berk. "They also update the progress coming out of ADNI, the Alzheimer"s Disease Neuroimaging Initiative, and describe how some amazing diagnostic tools have now been incorporated into the pivotal trials of these exciting therapeutics." Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca/Targacept, Avid, Baxter, Bayer-Schering/Avid Radiopharmaceuticals, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Elan/Transition Therapeutics/AZ, Elan/Wyeth, Envivo, Eisai, Forest/Merz/Lundbeck/Daiichi-Sankyo, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Link, Myriad, Novartis, Oligomerix, Pfizer, Pfizer/Medivation, Prana, Roche/Memory, Satori, TauRx, TauTaTis, Transtech, and Wyeth. About MedPredict MedPredict maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity. MedPredict


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009